ESMO 2020: Pembrolizumab Fails to Offer Benefits Over Cetuximab When Combined With Radiotherapy for Advanced Head and Neck Cancer
A study based on programmed cell death-ligand 1 status is currently underway
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.